TITLE

VANDA PHARMACEUTICALS

AUTHOR(S)
Investor's Business Daily
PUB. DATE
November 2013
SOURCE
Investors Business Daily;11/15/2013, pA02
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the growth of sales at drug manufacturer Vanda Pharmaceuticals Inc. as of November 2013 and mentions the launch of its experimental drug that aids blind people sleep.
ACCESSION #
91992193

 

Related Articles

  • Circadian rhythm drug approved. Tsuey Tse, Man // Nature Biotechnology;Apr2014, Vol. 32 Issue 4, p303 

    The article focuses on Vanda Pharmaceuticals' Hetlioz (tasimelteon) which is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat non-24 sleep-wake disorder.

  • Rhythm, no blues: Vanda sleep therapy wins FDA clearance. Osborne, Randy // BioWorld Today;2/3/2014, Vol. 25 Issue 22, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Vanda Pharmaceutical Inc. for its Hetlioz, a selective melatonin receptor agonist for non-24-hour wake-sleep disorder. It mentions the schedule of the launch of the drug in the market and provides...

  • FDA Grants Priority Review to Vanda's Tasimelteon. Shaffer, Catherine // BioWorld Today;7/31/2013, Vol. 24 Issue 145, p1 

    The article reports on the priority review status granted by the U.S. Food and Drug Administration (FDA) to Vanda Pharmaceuticals Inc. for tasimelteon, its candidate for non-24-hour disorder in people who are totally blind. The compound is a dual melatonin receptor agonist with selective...

  • Despite Endpoint Furor, FDA Panel Unanimously Backs Vanda's Hetlioz. Shaffer, Catherine // BioWorld Today;11/15/2013, Vol. 24 Issue 221, p1 

    The article discusses the uproar caused after the new sleep drug Tasimelteon from the U.S.-based Vanda Pharmaceuticals Inc. was voted as safe and effective for the treatment of non-24-hour sleep-wake disorder by the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System...

  • Sleep Disorders Update.  // PharmaWatch: CNS;Jun2007, Vol. 6 Issue 6, p12 

    The article offers news briefs related to the treatment of sleep disorders in the U.S. The U.S. Food and Drug Administration (FDA) has approved 13 generic alternatives to Sanofi-Aventis' insomnia drug Ambien. FDA ensures that generic drugs are safe and effective for the American public through a...

  • FDA Committee Meeting to Illuminate Vanda Sleep Drug. Shaffer, Catherine // BioWorld Today;11/13/2013, Vol. 24 Issue 219, p1 

    The article focuses on the advisory committee meeting of the U.S. Food & Drug Administration (FDA), to be held on November 14, 2013, regarding tasimelteon, a drug therapy developed by Vanda Pharmaceuticals Inc. for non-24-hour disorder, a sleep disorder in which the circadian rhythm of the body...

  • Fanapt for schizophrenia.  // MPR - Long Term Care Edition;May2009, Vol. 4 Issue 1, pA7 

    The article evaluates the receptor antagonist Fanapt from Vanda.

  • FINANCINGS.  // BioWorld Today;8/8/2013, Vol. 24 Issue 151, p6 

    The article reports on the total shares of common stock that was sold by Vanda Pharmaceuticals Inc. in an underwritten public offering to be used for the commercial launch activities for tasimelteon.

  • Clinic Roundup.  // BioWorld Today;8/30/2010, Vol. 21 Issue 167, p2 

    This section offers news briefs on drug trials, including the Phase I trial of the schizophrenia and anxiety compound ADX71149 from Addex Pharmaceuticals Ltd, a Phase III trial initiated by Vanda Pharmaceuticals Inc. for its Tasimelteon drug in patients with non-24-hou sleep wake diorder and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics